Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Class A Common Stock, par value $0.001 per share
-
Shares outstanding
-
64M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
16.9M
-
Shares change
-
-329K
-
Total reported value, excl. options
-
$130M
-
Value change
-
-$5.08M
-
Number of buys
-
31
-
Number of sells
-
-15
-
Price
-
$7.68
Significant Holders of Immuneering Corp - Class A Common Stock, par value $0.001 per share (IMRX) as of Q3 2023
55 filings reported holding IMRX - Immuneering Corp - Class A Common Stock, par value $0.001 per share as of Q3 2023.
Immuneering Corp - Class A Common Stock, par value $0.001 per share (IMRX) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.9M shares
of 64M outstanding shares and own 26.48% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (4.2M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.53M shares), BlackRock Inc. (2.51M shares), CITADEL ADVISORS LLC (2.07M shares), VANGUARD GROUP INC (1.04M shares), FMR LLC (612K shares), GOLDMAN SACHS GROUP INC (483K shares), GEODE CAPITAL MANAGEMENT, LLC (433K shares), STATE STREET CORP (361K shares), and TD Asset Management Inc (284K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.